Cvs (CVS) Stock
Retail pharmacy giant with insurance and care services. Here's the price, business snapshot, and what's worth knowing about Cvs in May 2026.
CVS Health Corporation is a large integrated healthcare company combining retail pharmacies, pharmacy benefit management (Caremark), and a health insurance arm following its acquisition of Aetna. With a market capitalisation around $105.3bn, CVS aims to offer end-to-end care solutions — from prescriptions and in-store clinical services (MinuteClinic) to care management and insurance products. Investors should note the company’s diversified revenue streams and potential cost synergies from vertical integration, but also be aware of material regulatory, reimbursement and competitive risks. Profitability depends on drug pricing dynamics, insurance margins, and effective cost control across vast retail and clinical operations. The business carries a significant debt load from past acquisitions, so interest-rate sensitivity and cash generation matter. CVS has historically returned cash to shareholders and can be of interest to income and value-oriented investors, though performance can vary and this is general information, not investment advice.
Why It's Moving
CVS is drawing analyst support as the 2026 outlook reflects modest upside and a steadier healthcare backdrop.
- Analyst forecasts remain constructive, with consensus targets implying roughly high-teens upside versus recent trading levels, which signals continued confidence in CVS’s recovery path.
- Recent commentary has pointed to operational and regulatory pressures across managed care and pharmacy benefits, keeping investors focused on how CVS protects margins rather than on top-line growth alone.
- The stock is still being viewed through a defensive-healthcare lens, meaning any signs of steadier reimbursement trends, claims normalization, or improved execution can quickly lift sentiment.
CVS is drawing analyst support as the 2026 outlook reflects modest upside and a steadier healthcare backdrop.
- Analyst forecasts remain constructive, with consensus targets implying roughly high-teens upside versus recent trading levels, which signals continued confidence in CVS’s recovery path.
- Recent commentary has pointed to operational and regulatory pressures across managed care and pharmacy benefits, keeping investors focused on how CVS protects margins rather than on top-line growth alone.
- The stock is still being viewed through a defensive-healthcare lens, meaning any signs of steadier reimbursement trends, claims normalization, or improved execution can quickly lift sentiment.
When is the next earnings date for CVS (CVS)?
The next CVS earnings date is expected around July 30, 2026; CVS has not officially confirmed the date yet. It will cover Q2 2026 results. Based on CVS’s historical reporting pattern, the release is typically scheduled for late July or early August, usually before the market opens.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding CVS’s stock, as its target price is slightly above its current price.
Financial Health
CVS is performing well with strong profitability, cash flow, and revenue, indicating solid financial health.
Dividend
CVS's dividend yield of 2.85% offers a decent return for those seeking dividends. If you invested $1000, you would be paid $28.50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CVS
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketWalgreens Restructuring Explained: Investment Shifts
Following its acquisition by Sycamore Partners, Walgreens has gone private and split into five companies. This theme explores the investment opportunities created by the newly independent healthcare and retail entities.
Published: September 2, 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: August 29, 2025
Explore BasketMedicaid Politics
Discover companies whose fortunes are closely tied to government healthcare funding decisions. These carefully selected stocks represent businesses with significant exposure to Medicaid, now facing heightened legislative uncertainty after Senator Tillis's retirement.
Published: June 30, 2025
Explore BasketNeuro-Inclusive Employers
Explore companies that are tapping into neurodivergent talent as a strategic advantage. These forward-thinking organizations have established dedicated programs for recruiting and supporting employees with autism, ADHD, and other forms of neurodivergence, potentially driving innovation and long-term growth.
Published: June 17, 2025
Explore BasketEmployee Mental Health As A Benefit
Discover companies transforming workplace wellness through innovative mental health solutions. These carefully selected stocks represent businesses helping corporations attract and retain talent by offering digital therapy, virtual counseling, and wellness technologies as employee benefits.
Published: June 17, 2025
Explore BasketStagflation Standouts
This collection features stocks and assets carefully selected by professional analysts to potentially outperform during stagflation periods. These defensive investments have already shown strength while the broader market struggles, making them worth consideration for economic uncertainty ahead.
Published: May 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Integrated care model
Vertical integration across pharmacies, PBM and insurance can create efficiencies and cross-selling opportunities, though benefits depend on successful integration and regulation.
Scale and reach
A large national footprint and broad customer base support stable prescription volumes, but competition from other chains and online players can pressure margins.
Services and tech
Investors may watch digital services, care management and cost controls as potential growth drivers, while remembering that execution and regulatory shifts add uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
